•  
  •  
 

The Thai Journal of Veterinary Medicine

Abstract

Six dogs were diagnosed with pulmonary hypertension (PH) secondary to chronic degenerative mitral valve disease (CDMVD) on echocardiography. Imatinib (3 mg/kg, every 24 hours, PO) was initiated without any changes to the background therapy to treat the PH. Follow-up evaluations at 1, 3, 5 and 6 months revealed substantial clinical and hemodynamic improvements. One dog showed deterioration after the imatinib withdrawal to necessitate a restart therapy. No side effects were observed throughout the 6-month treatment course. Low-dose imatinib may provide a promising treatment alternative for CDMVD-associated PH in dogs.

DOI

10.56808/2985-1130.2939

First Page

499

Last Page

505

Share

COinS